Clinical trial
Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65…
NCT00481546 · University of Pennsylvania, Other · Active, not recruiting
Key facts
| NCT number | NCT00481546 |
|---|---|
| Title | Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations |
| Official title | Phase I Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-CBSB-hRPE65) Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations (Clinical Trials of Gene Therapy for Leber Congenital Amaurosis) |
| Acronym | LCA |
| Lead sponsor | University of Pennsylvania, Other |
| Collaborators | National Eye Institute (NEI) NIH |
| Status | Active, not recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Amaurosis of Leber, Retinal Diseases |
| Intervention type | Genetic |
| Interventions | rAAV2-CBSB-hRPE65 |
| Enrollment | 15 |
| Start date | Jul 1, 2007 |
| Primary completion | Jun 1, 2026 |
| Completion | Jun 1, 2026 |
| First posted | Jun 1, 2007 |
| Last update posted | Aug 5, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: